Having just been appointed chief operating officer of contract manufacturing services organization (MSA) Lykan Bioscience, Patrick Lucy reflects on an illustrious career in the biopharma space and the parallels of today's cell and gene therapy landscape with that of monoclonal antibodies 30 years ago.
